We are delighted to present the anniversary Research Topic, “16 Years with Frontiers in Oncology.” This milestone collection celebrates the groundbreaking research and global collaboration that have shaped the field of oncology since the journal’s inception.
Over the past 16 years, Frontiers in Oncology has published pioneering studies that have advanced our understanding of cancer biology, diagnostics, and therapeutics. This commemorative collection aims to highlight both the remarkable progress achieved to date and the exciting directions shaping the future of oncology research.
We welcome contributions that reflect the breadth and diversity of cancer research, from fundamental discoveries and innovative methodologies to translational and clinical applications. Topics of interest include, but are not limited to:
- Mechanisms of tumorigenesis and resistance
- Development and optimization of anticancer therapeutics and delivery systems
- Integration of artificial intelligence and precision medicine in oncology
- Advances in cancer prevention, screening, and survivorship
- Cross-disciplinary approaches combining pharmacology, molecular biology, and clinical practice
Each speciality section within Frontiers in Oncology will showcase exemplary work that represents its unique focus, from Pharmacology of Anticancer Drugs, emphasizing novel therapeutic strategies and personalized medicine, to Breast Cancer, highlighting innovations in diagnosis, treatment, and survivorship.
We extend our sincere gratitude to our authors, reviewers, and editors for their continued contributions to advancing open-access cancer research. To mark this milestone, accepted articles will receive increased visibility through targeted promotion across our channels and events.
Join us in celebrating 16 years of impactful oncology research by contributing your work to this special collection, as we continue to drive innovation and improve patient outcomes worldwide.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases, which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.

Are you interested in contributing a manuscript to this Research Topic?

16 Years with Frontiers in Oncology: Celebrating Excellence and Innovation in Cancer Research